Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on April 6, 2020, covering events that occurred on April 3, 2020. The filing details two significant strategic agreements entered into with Dicerna Pharmaceuticals, Inc. regarding intellectual property cross-licensing and a new development collaboration.
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt figures. The financial implications are limited to the terms of the new agreements:
- Primary Hyperoxaluria (PH) Cross-License: Alnylam will pay mid- to high-single-digit royalties to Dicerna on global net sales of lumasiran. Dicerna will pay low-single-digit royalties to Alnylam on global net sales of nedosiran.
- Alpha-1 Liver Disease Collaboration: Dicerna assumes development costs for both ALN-AAT02 and DCR-A1AT. Future financial terms depend on Alnylam's opt-in decision for commercialization outside the U.S., involving tiered royalties or milestone payments.
Material Changes
The primary material change is the entry into two definitive agreements with Dicerna Pharmaceuticals:
- Patent Cross-License Agreement: Grants non-exclusive licenses for intellectual property related to investigational RNAi products for primary hyperoxaluria (lumasiran and nedosiran). This ensures freedom to operate for both parties in this therapeutic area.
- Development and Commercialization Collaboration: Establishes a partnership to explore RNAi therapeutics for alpha-1 antitrypsin deficiency-associated liver disease. Dicerna takes the lead on clinical development and candidate selection.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreements aim to accelerate the development of RNAi therapeutics for rare diseases. Alnylam retains the option to commercialize the selected alpha-1 liver disease candidate outside the U.S. at no cost upon completion of Phase 3 development.
Risks and Contingencies:
- Regulatory Approval: The Collaboration Agreement is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
- Patent Challenges: The Cross-License Agreement allows for termination or royalty reduction if either party challenges the other's patents, unless the challenge is withdrawn within specified timeframes.
- Development Uncertainty: Dicerna will select which product candidate(s) to advance for alpha-1 liver disease, introducing uncertainty regarding which asset Alnylam may eventually commercialize.
Key Facts for Investor Verification
- Verify the specific royalty percentages defined as "mid- to high-single-digit" and "low-single-digit" in the full Cross-License Agreement text.
- Confirm the status of the Hart-Scott-Rodino waiting period for the Collaboration Agreement.
- Monitor Dicerna's selection of the lead candidate for alpha-1 liver disease, as this determines Alnylam's future commercialization rights and revenue potential.
- Review the full text of the agreements when filed as exhibits to the Form 10-Q for the quarter ending June 30, 2020.